SOS article today. I agree with his comments below.
"The stock was trading at $0.23 on the last trading day prior to the release of the manuscript on May 29. Now one week later, it is trading at $0.28. If anyone doubts that stock trading on small, emerging companies can be and often is rigged, you only need look to this stock behavior. The wolfpack and the market makers they conspire with can actually set the price of NWBO, at least for now. This is one of the largest criminal enterprises in the US affecting not just NWBO but many, many small companies.
The immediate intent of the wolfpack is to give the appearance that the spectacular clinical data is being received skeptically by investors and to discourage both current and potential shareholders. NWBO at the current price has a market capitalization of $122 million based on fully diluted shares as reported in the latest 10-Q and $230 million if every potential share equivalent were converted to common. In my opinion and based on my experience, if NWBO were a private company with the current clinical data and elected to come public, the offering would be priced at a market capitalization of $1.5 to $2.0 billion, would be quickly over-subscribed and quickly rise to a substantial premium over the offering price."
News 
Market Data 
Discover 
